v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2026
Sep. 30, 2025
REVENUE:    
Total revenue $ 280,007 $ 328,811
OPERATING COSTS AND EXPENSES:    
Cost of commissions and other services revenue 61,753 69,101
Cost of goods sold—pharmacy revenue 155,263 192,779
Marketing and advertising 46,439 61,947
Selling, general, and administrative 35,911 35,819
Technical development 9,228 9,911
Total operating costs and expenses 308,594 369,557
LOSS FROM OPERATIONS (28,587) (40,746)
Interest expense, net (10,966) (11,808)
CHANGE IN FAIR VALUE OF WARRANTS 12,573 15,036
OTHER INCOME (EXPENSE), NET 463 (145)
LOSS BEFORE INCOME TAX BENEFIT (26,517) (37,663)
INCOME TAX BENEFIT (6,216) (7,204)
NET LOSS (20,301) (30,459)
Senior Non-Convertible Preferred Stock accumulated dividends and accretion (20,161) (17,482)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (40,462) $ (47,941)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE:    
Basic (in dollars per share) $ (0.21) $ (0.26)
Diluted (in dollars per share) $ (0.21) $ (0.26)
WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:    
Basic (in shares) 191,459 185,816
Diluted (in shares) 191,459 185,816
Commissions and other services    
REVENUE:    
Total revenue $ 95,963 $ 110,267
Pharmacy    
REVENUE:    
Total revenue $ 184,044 $ 218,544